Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC)
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Severe traumatized patients with visible significant bleeding and/or with clinical signs of internal significant bleeding treated by an emergency doctor of the helicopter service or the ground team will be enrolled in the study (inclusion- and exclusion criteria: see above). If a patient meets the inclusion criteria and is recruited for the study, his baseline values on the scene (T1) will first be collected including the first blood collection as well as documentation of the clinical parameters (hemodynamics, respiratory and neurological function, etc.). Subsequently, 30 patients will be randomized to receive about 50 mg/kg BW fibrinogen concentrate (one vial for each 30 kg body weight, estimated by the emergency physician), while the other 30 patients receive placebo (also one vial including 100 ml for each 30 kg body weight). The flow rate should not exceed 100 ml within 5 minutes.
FGTW or placebo administrated over 5 min/vial:
Body Weight: < 30 kg / 30-60 kg / 60 - 90 kg / > 90 kg
No. of vials: 1 vial (100 ml) / 2 vials (200 ml) / 3 vials (300 ml) / 4 vials (400 ml)
Fibrinogen (if applicable): 1.5 g / 3 g / 4.5 g / 6 g
Immediately after admission to hospital, the patient's parameters including blood collection (see below) will be measured for the second time (T2), if applicable, after the end of administration of the study drug. Additional measurements will be made 3 hours (T3), 9 hours (T4), and 24 hours (T5), 48 hours (T6) and one week after admission (T7). 30 days after inclusion in the study, a final investigation is planned (T8).
Coagulation management after admission to hospital is depending on the specific demands of the patient and should be performed according to the recommendations of the Austrian Society for Anaesthesiology, Intensive Care Medicine and Resuscitation (ÖGARI) (http://www.oegari.at/web_files/dateiarchiv/116/key%20messages%20management%20of%20TIC%202011.pdf). Blood loss, transfusion requirements, volume therapy and coagulation therapy will be documented.
When the bleeding is under control thromboprophylaxis has to be performed according to the international standard of care earliest after 24 hours after cessation of bleeding (preferably using enoxaparin).
| Condition | Intervention | Phase |
|---|---|---|
|
Trauma Major Bleeding |
Drug: Human Fibrinogen Drug: Placebo |
Phase 1 Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Investigator) Primary Purpose: Treatment |
| Official Title: | A Multicenter Double-blind, Placebo Controlled, Randomized, Pilot Trial to Assess the Efficacy of Pre-hospital Administration of Fibrinogen Concentrate (FGTW) in Trauma Patients, Presumed to Bleed (FI in TIC) |
- Change of the Fibrinogen polymerisation measured with FIBTEM® MCF [ Time Frame: The average period for the measurement (MCF) of the primary outcome is 60 minutes . Timepoints of measurements: Emergency scene (minute 0) and arrival to the hospital (on average after 60 minutes). ] [ Designated as safety issue: No ]Further measurements and investigations will be done until 7 days after the hospital admission. The patient will be followed up until 30 days (final interview).
| Estimated Enrollment: | 60 |
| Study Start Date: | September 2011 |
| Estimated Primary Completion Date: | September 2013 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: FGTW |
Drug: Human Fibrinogen
intravenous
|
| Placebo Comparator: Placebo |
Drug: Placebo
intravenous
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Trauma patient
- Patient at the obvious age of equal or higher than 18 years of either sex
- Major bleeding or occult bleeding with parameters of shock
- Need for volume replacement therapy
Patient, who will be admitted to one of the participating hospitals:
- A01 Medical University Innsbruck
- A02 Emergency Hospital Salzburg
- A03 PMU Salzburg
- A04 Regional Hospital Vöcklabruck
- A05 Medical University Graz
Exclusion Criteria:
- Penetrating trauma
- Solely head injury
In case of hemodynamic instability:
Patient has to be excluded if the hemodynamic stabilisation (SBP below 90 mmHg and HR more than 100 per min) is not achieved after 15 minutes of resuscitation management in spite of volume therapy and administration of catecholamines
- Patient with inevitable lethal course as evaluated by emergency physician
- Need for CPR on the scene
- Deep hypothermia (below 30°C)
- Obviously pregnant women
- Patient with known recent history of thromboembolic events within the last 6 months
- Patient known to be on anticoagulant therapy
- Patient with known refusal of a participation in this clinical trial
Contacts and Locations| Contact: Pamela Schech | +43512504 ext 80450 | pamela.schech@i-med.ac.at |
| Contact: Mirjam Bachler, MA. | +43512504 ext 80451 | mirjam.bachler@i-med.ac.at |
| Austria | |
| Christophorus 12 | Not yet recruiting |
| Feldkirchen, Austria, 8073 | |
| Contact: Thomas Raber, OA MD +43316385 ext 81759 thomas.raber@medunigraz.at | |
| Principal Investigator: Thomas Raber, OA MD | |
| University Hospital Graz | Not yet recruiting |
| Graz, Austria, 8036 | |
| Contact: Thomas Raber, OA MD +316385 ext 81759 thomas.raber@medunigraz.at | |
| Principal Investigator: Thomas Raber, OA MD | |
| Medical University Innsbruck | Recruiting |
| Innsbruck, Austria, 6020 | |
| Contact: Pamela Schech +43512504 ext 80450 pamela.schech@i-med.ac.at | |
| Principal Investigator: Dietmar Fries, Prof. MD | |
| NEF Innsbruck | Active, not recruiting |
| Innsbruck, Austria, 6020 | |
| Christophorus 1 | Recruiting |
| Innsbruck, Austria, 6020 | |
| Contact: Marc Kaufmann, MD +43512504 ext 80471 marc.kaufmann@uki.at | |
| Principal Investigator: Marc Kaufmann, MD | |
| Martin 2 | Recruiting |
| Karres, Austria, 6462 | |
| Contact: Christian Niederwanger, MD +43512504 ext 82732 christian.niederwanger@uki.at | |
| Principal Investigator: Christian Niederwanger, MD | |
| Christophorus 4 | Active, not recruiting |
| Kitzbühel, Austria, 6370 | |
| Christophorus 14 | Recruiting |
| Niederöblarn, Austria, 8960 | |
| Contact: Christine Haas, MD +436506344266 christine.haas@kages.at | |
| Principal Investigator: Christine Haas, MD | |
| AUVA Trauma Center | Recruiting |
| Salzburg, Austria, 5020 | |
| Contact: Herbert Schöchl, MD +436626580 ext 5877 herbert.schoechl@auva.at | |
| Principal Investigator: Herbert Schoechl, MD | |
| University Hospital Salzburg (PMU)/Regional Hospital Salzburg | Active, not recruiting |
| Salzburg, Austria, 5020 | |
| Christophorus 6 | Recruiting |
| Salzburg, Austria, 5020 | |
| Contact: Bernhard Ziegler, OA MD +436624482 ext 2701 b.ziegler@salk.at | |
| Principal Investigator: Bernhard Ziegler, OA MD | |
| NEF Stadt Salzburg | Active, not recruiting |
| Salzburg, Austria, 5020 | |
| Regional Hospital Vöcklabruck | Active, not recruiting |
| Vöcklabruck, Austria, 4840 | |
| NAW Vöcklabruck | Active, not recruiting |
| Vöcklabruck, Austria, 4840 | |
| Principal Investigator: | Dietmar Fries, Prof. MD | Medical University Innsbruck |
More Information
No publications provided
| Responsible Party: | Dietmar Fries, M.D., Coordinating and Principal Investigator, Medical University Innsbruck |
| ClinicalTrials.gov Identifier: | NCT01475344 History of Changes |
| Other Study ID Numbers: | FIinTIC |
| Study First Received: | October 27, 2011 |
| Last Updated: | November 21, 2012 |
| Health Authority: | Austria: Federal Office for Safety in Health Care |
Keywords provided by Medical University Innsbruck:
|
Trauma patient with major bleeding |
Additional relevant MeSH terms:
|
Hemorrhage Wounds and Injuries Pathologic Processes |
ClinicalTrials.gov processed this record on May 23, 2013